A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.
about
A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A 6-week, double-blind, placeb ...... ents with acute schizophrenia.
@ast
A 6-week, double-blind, placeb ...... ents with acute schizophrenia.
@en
type
label
A 6-week, double-blind, placeb ...... ents with acute schizophrenia.
@ast
A 6-week, double-blind, placeb ...... ents with acute schizophrenia.
@en
prefLabel
A 6-week, double-blind, placeb ...... ents with acute schizophrenia.
@ast
A 6-week, double-blind, placeb ...... ents with acute schizophrenia.
@en
P2093
P2860
P356
P1476
A 6-week, double-blind, placeb ...... ents with acute schizophrenia.
@en
P2093
John Guarino
Steven G Potkin
Tatsuya Kimura
P2860
P304
P356
10.1177/2045125315606027
P577
2015-12-01T00:00:00Z